title: High-density lipoprotein cholesterol function improves after successful treatment of psoriasis: a step forward in the right direction.
abstract: There is epidemiological evidence that high-density lipoprotein (HDL) concentrations, or HDL "levels," exert protection from atherosclerosis, suggesting that HDL plays a role in vascular diseases. More accurate measures of HDL "function" are emerging, such as HDL efflux assays, which measure removal of cholesterol from peripheral tissues. Using this assay, we have demonstrated that psoriasis is associated with decreased HDL "levels" and HDL "function." The study by Holzer et al. in this issue demonstrates in an open-label, uncontrolled study that HDL function is impaired in psoriasis and improves after successful treatment of psoriasis. These findings underscore the notion that treatment of psoriasis likely extends beyond the skin and that a randomized controlled clinical trial is needed to confirm these findings.
authors: National Heart, Lung and Blood Institute, Bethesda, Maryland, USA. Electronic address: nehal.mehta@nih.gov.
authors: Nehal N
authors: NN
authors: Mehta
authors: Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA; Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
authors: Joel M
authors: JM
authors: Gelfand
mesh_terms: D005260:Female; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood*; D008264:Macrophages / Q000378:metabolism*; D008297:Male; D011701:PUVA Therapy; D011565:Psoriasis / Q000188:drug therapy* / Q000378:metabolism*
chemical_list: D008075:Lipoproteins, HDL